Neoplasms

All Conditions

Symptoms and General Pathology

Adenocarcinoma

Neoplasm Metastasis

Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Antineoplastic Agents

All Drugs and Chemicals

Bevacizumab

Antineoplastic Agents, Immunological

Angiogenesis Inhibitors

Growth Inhibitors

Bevacizumab will be administered according to investigators appreciation.

Blood samples will be collected at enrollment, at second bevacizumab's administration and every 10 weeks until progression, or until patients stop bevacizumab because of toxicity or until one year at most in case that patients still receive bevacizumab.

Bevacizumab + blood samples

Christelle DE LA FOUCHARDIERE, MD

It is a prospective, non-randomized, monocentric study. The purpose of the study is to assess the predictive value of VE-cadherin on the objective tumor response.

Biological factors will be correlated to clinical outcome measures.

100 patients treated with bevacizumab for a metastatic colorectal adenocarcinoma will be enrolled.

Patients will be followed every 10 weeks until progression in spite of bevacizumab or until they stop bevacizumab because of toxicity.

Bevacizumab will be administered according to investigators appreciation.

Blood samples will be collected at enrollment, at second bevacizumab's administration and every 10 weeks until progression, or until patients stop bevacizumab because of toxicity or until one year at most in case that patients still receive bevacizumab.

Exploration of Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab

Exploration of New Biologic Factors' Predictive Value , Especially Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab

A 30% response rate (complete or partial response) to treatment is expected. The response will be assessed according to RECIST criteria. This primary outcome measure is defined by the observation of at least one objective response during the treatment.

This outcome measure will be correlated to biological factors.

The clinical benefit is based on complete response, partial response or stable disease.

This outcome measure will be correlated to biological factors.

This outcome measure will be correlated to biological factors.

Assess the link between vascular toxicities and VE-cadherin rate. These toxicities will be assessed during the follow-up of patients.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Exploration of Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab	NCT01405430	Colorectal Canc... Metastasis	Bevacizumab + b...	18 Years -	Centre Leon Berard
Exploration of Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab	NCT01405430	Colorectal Canc... Metastasis	Bevacizumab + b...	18 Years -	Centre Leon Berard

Spots Global Cancer Trial Database for bevacizumab + blood samples